TABLE 1.

Clinicopathological characteristics and their associations with the expression level of NTNG1 in ovarian cancer tissues.

Clinicopathological variables	Case no.	NTNG1 expression level		p-value
		Low (n = 39)	High (n = 28)
Age (year)
<50	23	13 (56.5%)	10 (43.5%)	0.840
≥50	44	26 (59.1%)	18 (40.9%)
Histological type
Serous	59	34 (57.6%)	25 (42.4%)	0.386
Clear cell	7	5 (71.4%)	2 (28.6%)
Endometrioid	1	0 (0.0%)	1 (100.0%)
Pathological grade
1/2	25	12 (48.0%)	13 (52.0%)	0.191
3	42	27 (64.3%)	15 (35.7%)
Category
Type I	32	17 (53.1%)	15 (46.9%)	0.420
Type II	35	22 (62.9%)	13 (37.1%)
FIGO stage
I/II	22	15 (68.2%)	7 (31.8%)	0.247
III/IV	45	24 (53.3%)	21 (46.7%)
Cisplatin response*
Resistant	23	7 (30.4%)	16 (69.6%)	0.001
Sensitive	44	32 (72.7%)	12 (27.3%)

*Resistance was that tumors recurred or progressed within 6 months from the last dose, and sensitivity was that tumors relapsed after 6 months.